Acute and Chronic Leukemias

CCO&rsquo s expert faculty review and share their expert perspectives on key findings in acute and chronic leukemias presented at the 2019 ASH annual meeting.

Share

Program Content

Activities

  • ASH 2019: Leukemias
    Leukemias: Key Trials From ASH 2019
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 03, 2020

    Expires: February 01, 2021

Activities

E2906: DAC Maintenance
ECOG-ACRIN E2906: Maintenance Decitabine After Response to Intensive Therapy in Older AML Patients
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

TDT and Prognosis in AML
Analysis: Prognostic Effect of Time From Diagnosis to Treatment in Newly Diagnosed AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

FLAG-IDA plus Venetoclax in AML
Phase Ib/II Study: FLAG-IDA Plus Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2019

Expires: December 14, 2020

Frontline Ponatinib in ALL
First-line Hyper-CVAD Plus Ponatinib in Adults With Ph+ Acute Lymphoblastic Leukemia: Long-term Safety and Efficacy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2019

Expires: December 08, 2020

Venetoclax + Navitoclax in ALL/LL
Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2019

Expires: December 07, 2020

ENA + AZA in ND mIDH2 AML
Interim Phase II Results From AG221-AML-005: Enasidenib + Azacitidine vs Azacitidine Alone in Newly Diagnosed AML With IDH2 Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2019

Expires: December 15, 2020

R/R AML After VEN + HMA
Outcomes in R/R AML After First-line Treatment With Venetoclax Plus a Hypomethylating Agent
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2019

Expires: December 11, 2020

Ph+ ALL: Dasatinib + Blinatumomab
Updated Analysis of Frontline Dasatinib + Blinatumomab in Patients With Newly Diagnosed Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2019

Expires: December 16, 2020

Blinatumomab in B-ALL
Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2019

Expires: December 18, 2020

QUAZAR AML-001
QUAZAR AML-001: Phase III Study of CC-486 Maintenance Therapy in Patients With Acute Myeloid Leukemia in First Remission
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2019

Expires: December 13, 2020

Faculty

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company